Emris Pharma
Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients
Active
Pre-Seed
Startup
Nazareth
Founded 2023-05
EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy. Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition w…
SectorHealth Tech & Life Sciences
StagePre-Seed
Employees6
Founded2023-05
HQNazareth
Patents1
Confidence89
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technology
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals